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Stimulation of Corticotropin Release by Pentagastrin 
in Normal Subjects and Patients With Panic Disorder 
James L. Abelson, Randolph M. Nesse, and Aaron Vinik* 
ln oduction 
Patients with panic disorder have shown blunted 
corticotropin (ACTH) responses to corticotro- 
pin-releasing hormone (CRH) infusion (Roy- 
Byrne et al 1986). The precise mechanism 
underlying such blunting remains uncertain. 
Control of the hypo~lalamic-pituitary-adrenal 
(HPA) axis involves multiple hormonal regu- 
lators; but other regulators have received little 
attention. The availability of other regulators for 
infusion studies could advance our understand- 
ing of HPA axis function and help clarif:, the 
mechanisms underlying the blunted ACTH re- 
sponse to CRH. 
Cholecystokinin (CCK) and gastrin are cen- 
trally active neurotransmitters (Williams 1982) 
that appear to co-regulate HPA axis function, 
most likely through a brain receptor that is re- 
sponsive to both ""- ' :"""  (Reisine ,.,a ~ . . . . . .  Q It | t d t J l b ,  lt l ~ , , l l |  l-~Uttu~n 
1986; Saito et al 1980). ACTH and/or cortisol 
release in humans can be stimulated by large 
CCK-iike peptides (Spiith-Schwal~e et al 1988) 
and by small gastrinlike fragments (de Montigny 
1989; Degli Uberti et al 1983). 
Pentagastrin is a synthetic analogue that con- 
tains the same carboxy terminus tetrapeptide 
amide as CCK and gastrin. In one human study 
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it has been shown to be an active ACTH secre- 
tagogue (Degli Uberti et al 1983), but there are 
conflicting animal data (Itoh et al 1979). Its 
ready availability and proven safety record in 
human use, along with the evidence that a gas- 
trin/CCK-like peptide may co-regulate HPA ac- 
tivity, make pentagastrin a potentially valuable 
probe of t.he human stress-response system. To 
initiate development of this probe we attempted 
to confirm hhat pentagastrin is an ACTH secre- 
tagogue in humans and to pilot its use in a clin- 
ical population by conducting pentagastrin in- 
fusioas in ten subjects, five normal controls, and 
five pa:ients with panic disorder. We report here 
the ACTH and cortisol responses of these sub- 
jects. 
Methods 
All subjects gave informed consent, were drug- 
free for at least 2 weeks prior to study, were 
medically healthy, and were evaleated using a 
structured clinical interview. Panic patients met 
DSM-III-R criteria for panic disorder but did 
not m~t  criteria for current major depression 
or substance abuse and did not have any history 
of primary depression or psychosis. Control 
subjects were age and sex matched to the pa- 
tients and did not meet criteria for any Axis I 
disorder. Subjects were admitted to a clinical 
research center the night prior to study. They 
were awakened at 7:30 AM, and at 8:00 AM an 
indwelling heparin lock catheter was inserted 
into an ~tecubital vein. Three baseline blood 
samples were drawn, at 8:30, 8:45, and 8:59 
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AM. At 9:00 AM pentagastrin (commercially 
available as Peptavlon, Ayerst Laboratories) was 
infused into the heparin lock, for 1 min, at a 
dosage of 0.6 I~g)kg, in a saline vehicle of less 
than 1 ml. Blood samples were then drawn 1, 
3, 5, 7, 10, 15, 20, 30, 45, and 60 min after 
the infusion for ACTH assay and 5, 7, 10, 20, 
30, 45, and 60 min for cortisol assay. ACTH 
was measured by radioimmunoassay, with a 
sensitivity of 6 pg/ml and intraassay and inter- 
assay coefficients of variation of less than 10%. 
Cortisol was measured by high-performance liq- 
uid chromatography, with a sensitivity of 0.1 
Ixg/dl and coefficients of variation of less than 
6%. Anxiety symptoms were monitored re- 
peatedly throughout the procedure, using a mod- 
ified version of the Acute Panic Inventory (API) 
(Dillon et al 1987). 
Results 
One control subject had a resting norepinephrine 
level of over 1000 pg/ml and was dropped from 
the analyses. This resulted in a sample of nine 
subjects a control group of four women (mean 
age = 28.0 __. 6.3 years) and a patient group 
of four women and one man (mean age = 32.2 
__. 10.1 years). All five patients with panic dis- 
order had paniclike attacks in response to the 
pentagastrin infusion. Only one of the four con- 
trol subjects had a paniclike attack. These re- 
sponses have been described elsewhere (Abe!- 
son and Nesse 1990). 
Analysis of ACTH aata (repeated measures 
analysis of variance on log-transformed data) 
revealed a significant hormonal response to the 
infusion (main effect of time; F = 9.13, p < 
0.0001, df = 12,84). The ACTH response, 
shown graphically in Figure 1, began within 3 
min of infusion and disappeared within 30 min. 
It was substantial in size, with a mean peak 
response (postinfusion maximum minus mean 
baseline) of 79.0 pg/ml. Tukey's test showed 
significant elevations above baseline levels (p 
< 0.05) at 3, 5, 7, and 10 min after infusion 
(all subjec~ combined). Panic patients had el- 
evated mean baseline ACII-I levels (patient mean 
= 74.9 + 22.9 pg/ml; control mean = 43.8 
120. 
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Figure 1. Mean ACTH levels in patients and con- 
trois, before and after pentagastrin infusion. Infusion 
was given at time 0. 
___ 15.7 pg/ml; t = 2.47, p < 0.05, df = 7). 
The two groups did not differ on any measure 
of ACTH response to pentagastrin (area under 
the curve, net response, peak response), but panic 
patients had higher values on all of these mea- 
sures. The mean peak response, for example, 
was 88.6 pg/ml in patients and 66.9 pg/ml in 
controls. 
Analysis of cortisol tiara also tevealed a highly 
significant response to the infusion (main effect 
of time; F = 13.77, p < 0.0t,~l, df = 9,63). 
The cortisol response followed the time course 
expected in resnonse to the ACTH release de- 
scribed above. Tukey's test showed significant 
elevations above baseline levels (p < 0.05) at 
10, 20, and 30 rain after the infusion (all sub- 
jects cGmbined). Patient and control groups did 
not differ in mean baseline co~tisol levels (pa- 
tient mean = 14.6 +_ 4.7 ~g/dl; control mean 
= 11.0 ___ 2 . 5 ~ g / d l ; t  = 1.35, p > 0 . 2 0 ,  df 
= 7). However, panic patiems did have a sig- 
nificantly greater area under the postinfusion ~ -  
sponse curve (patient mean = 780 -- 145; con- 
trol mean = 564 +__ 97; t = 2.53, p < 0.05, 
df = 7), and the group differences in net re- 
sponse (postinfusion area minus preinfasion area) 
approached significance (patient mean = 320 
___ 62; control mean = 216 +_ 78; t = 2.26, 
p < 0.06, df = 7). 
The ratio of ACTH to cortisol response (area 
under postinfusion response curve for ACTH 
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divided by area under the postinfusion response 
curve for cortisol) was calculated for each sub- 
ject. The two groups had nearly identical ratios 
(8.5 ___ 2.5 for panic patients and 8.8 • 4.4 
for controls; t = 0.12, p > 0.90, df -- 7). 
The correlation between mean baseline cor- 
tisol and net ACTH response was small and non- 
significant (r = 0.136, p > 0.70). There was 
no relationship between net ACTH response and 
subjective symptom response to the infusion 
(calculated by subtracting total symptom sever- 
ity on the preinfusion API from total peak symp- 
tom severity postinfusion; r = -0 .43,  p > 
0.20). Peak ACTH response and peak postin- 
fusion symptom levels also showed a nonsig- 
nificant, negative correlation (r = - 0.45, p > 
0.20). 
Discussion 
The data confirm that pentagastrin produces sig- 
nificant rises in both ACTH and cortisol and 
demonstrate that this peptide provides an easily 
used and potent stimulus to the human HPA 
axis. The mechanism cannot be determined from 
our data, but the time course of the response 
and its lack of relationship to basal cortisol lev- 
els suggest that it was not mediated by CRH. 
Anxiety symptoms also do not appear to have 
mediated the ACTH responses seen. Correla- 
tions between symptoms and ACTH responses 
were insignificant and negative. Those subjects 
with the most intense paniclike symptoms had 
the smallest ACTH responses. The three sub- 
jects with the largest AC~i'H respons¢~ were the 
least symptomatic in their groups. Panic attacks 
themselves do not produce the kind of HPA 
activation that we saw in response to pentagas- 
trin (Cameron et al 1987; Levin et al 1987; Woods 
et al 1987). Additional research is necessary to 
verify our hypothesis that the ACTH response 
to pentagastrin results from direct pharmaco- 
logical effect on the pituitary corticotroph cell. 
The implications of our patient-control com- 
parisons must be considered tentative until we 
have enlarged our sample sizes, but tile i, otential 
utility of this new probe is illustrated by the 
intriguing possibility that panic patients have 
HPA axis responses to pentagastrin that differ 
from their HPA responses to CRH. Panic pa- 
tients appear to have normal or increased HPA 
axis responsivity to pentagastrin (compared with 
controls they had greater postinfusion cortisol 
levels, normal ACTHJcortisol ratios, and higher 
values on all measures of ACTH response), 
whereas prior reports have demonstrated blunted 
ACTH responses to CRH in panic patients 
(Holsboer et al 1987; Roy-Byme et al 1986). A 
variety of mechanisms could contribute to dif- 
fering ACTH responses to two different releas- 
ing factors. These include differing sensitivity 
to glucocorticoid inhibition, specific desensiti- 
zation of the corticotroph cell to one factor, or 
differing intraceUular mediating mechanisms. It 
is interesting to note that CRH stimulates ACTH 
release through an adenylate cyclase-cyclic 
adenosine monophosphate-dependent process 
(Axelrod and Reisine 1984); CCK-stimulated 
release of ACTH does not require cAMP (Re- 
isine and Jensen 1986); and panic patients have 
reduced platelet adenylate cyclase activity 
(Chamey et al 1989). Before proceeding to 
mechanistic studies, replication of our pilot find- 
ings in larger samples is needed, but subsequent 
combined use of pentagastrin and CRH infusion 
probes may be able to shed light on the mech- 
anisms underlying HPA axis abnormalities in 
panic. 
Our data confirm that pentagastrin stimulates 
ACTH release in humans and demonstrate the 
applicability of this neuroendocrine probe to 
psychiatric research. The data suggest that fur- 
ther study of this probe could provide unique 
opportunities for more precise elucidation of 
stress-response system abnormalities in psychi- 
atric disorders. 
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